Many survivors of stroke experience cognitive impairments that can range from mild deficits to more severe forms of dementia. Understanding the underlying mechanisms, developing accurate models of post-stroke cognitive decline, and identifying reliable risk factors and biomarkers are crucial for advancing our knowledge in this field and improving patient outcomes. A combination of vascular factors, neuroinflammation, neurodegenerative processes, and neuronal damage, all initiated and sustained by single or multiple stroke events, orchestrates the pathogenesis of post-stroke cognitive decline and dementia. Risk factors such as age, stroke severity, comorbidities, and genetic predispositions further influence the trajectory of cognitive decline. Accurate experimental models and human studies are needed to investigate these cognitive impairments observed in stroke survivors and the underlying mechanisms, find reliable biomarkers for early detection, prognosis, and monitoring of post-stroke cognitive decline and dementia, and discover potential interventions.
The primary goal of this Research Topic is to spotlight the latest findings about the intricate, stroke-triggered pathophysiological mechanisms leading to cognitive decline, encompassing discussion on relevant experimental models and human studies for the identification of biomarkers with potential translational perspective. By bringing together cutting-edge research findings, we aim to enhance our understanding of the processes underlying the cognitive consequences of stroke and facilitate the development of novel therapeutic strategies.
We welcome the submission of any type of manuscript supported by Frontiers in Stroke (including Original Research, Reviews, Brief Research Reports, etc.) on post-stroke cognitive decline and dementia, pertaining but not limited to the following themes:
- Pathogenesis of post-stroke cognitive decline, including neuroinflammation, disruption of the blood-brain barrier, neurotrophic factors, oxidative stress, synaptic dysfunction, and neurodegenerative processes.
- Advances in animal and human-derived models for the study of post-stroke cognitive decline.
- Identification of risk factors impacting the stroke-triggered pathogenetic mechanisms and the development of post-stroke cognitive decline.
- Identification of reliable biomarkers, both blood-based and imaging-based, that can aid in the early detection, prognosis, and monitoring of post-stroke cognitive decline and dementia.
- Exploration of therapeutic interventions targeting the pathogenetic processes initiated by stroke and underlying post-stroke cognitive decline, including pharmacological approaches and neurostimulation techniques.
- Translational studies bridging the gap between preclinical research and clinical practice, aiming to facilitate the translation of scientific discoveries into effective interventions for post-stroke cognitive impairments.
Dr. Paco Herson is a co-inventor of patents on peptide-based methods for treating neurological injuries (Patent No. PCT/US17/19140 and PCT/US/20/60681). No other competing interests are declared with regard to the Research Topic subject.
Many survivors of stroke experience cognitive impairments that can range from mild deficits to more severe forms of dementia. Understanding the underlying mechanisms, developing accurate models of post-stroke cognitive decline, and identifying reliable risk factors and biomarkers are crucial for advancing our knowledge in this field and improving patient outcomes. A combination of vascular factors, neuroinflammation, neurodegenerative processes, and neuronal damage, all initiated and sustained by single or multiple stroke events, orchestrates the pathogenesis of post-stroke cognitive decline and dementia. Risk factors such as age, stroke severity, comorbidities, and genetic predispositions further influence the trajectory of cognitive decline. Accurate experimental models and human studies are needed to investigate these cognitive impairments observed in stroke survivors and the underlying mechanisms, find reliable biomarkers for early detection, prognosis, and monitoring of post-stroke cognitive decline and dementia, and discover potential interventions.
The primary goal of this Research Topic is to spotlight the latest findings about the intricate, stroke-triggered pathophysiological mechanisms leading to cognitive decline, encompassing discussion on relevant experimental models and human studies for the identification of biomarkers with potential translational perspective. By bringing together cutting-edge research findings, we aim to enhance our understanding of the processes underlying the cognitive consequences of stroke and facilitate the development of novel therapeutic strategies.
We welcome the submission of any type of manuscript supported by Frontiers in Stroke (including Original Research, Reviews, Brief Research Reports, etc.) on post-stroke cognitive decline and dementia, pertaining but not limited to the following themes:
- Pathogenesis of post-stroke cognitive decline, including neuroinflammation, disruption of the blood-brain barrier, neurotrophic factors, oxidative stress, synaptic dysfunction, and neurodegenerative processes.
- Advances in animal and human-derived models for the study of post-stroke cognitive decline.
- Identification of risk factors impacting the stroke-triggered pathogenetic mechanisms and the development of post-stroke cognitive decline.
- Identification of reliable biomarkers, both blood-based and imaging-based, that can aid in the early detection, prognosis, and monitoring of post-stroke cognitive decline and dementia.
- Exploration of therapeutic interventions targeting the pathogenetic processes initiated by stroke and underlying post-stroke cognitive decline, including pharmacological approaches and neurostimulation techniques.
- Translational studies bridging the gap between preclinical research and clinical practice, aiming to facilitate the translation of scientific discoveries into effective interventions for post-stroke cognitive impairments.
Dr. Paco Herson is a co-inventor of patents on peptide-based methods for treating neurological injuries (Patent No. PCT/US17/19140 and PCT/US/20/60681). No other competing interests are declared with regard to the Research Topic subject.